Kymera Therapeutics Inc. has entered into a multi-program strategic collaboration with Sanofi to develop and commercialize first-in-class protein degrader therapies targeting IRAK4 in patients with immune-inflammatory diseases. The companies will also partner on a second earlier stage program. Kymera will receive $150 million upfront and may receive more than $2 billion in potential development, regulatory, sales milestones, as well as royalty payments. Kymera retains the option to participate i...